Aposture Surgical Corp discloses $150,000 SAFE offering in SEC Form D
The Philadelphia biotech, formerly BioSpine Corp, reported $87,000 raised toward the target as of a first sale date of August 7, 2026.
SEC filing
Latest
1 story
Sign inSign in1 story
The Philadelphia biotech, formerly BioSpine Corp, reported $87,000 raised toward the target as of a first sale date of August 7, 2026.
SEC filing